These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16998661)

  • 1. [Local recurrence of prostate cancer: hormone therapy].
    Altwein JE; Ebert T
    Urologe A; 2006 Oct; 45(10):1276, 1278-82. PubMed ID: 16998661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rising prostate-specific antigen after primary treatment of prostate cancer: sequential hormone manipulation.
    Schmid HP; Keuler FU; Altwein JE
    Urol Int; 2007; 79(2):95-104. PubMed ID: 17851276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01.
    Mydin AR; Dunne MT; Finn MA; Armstrong JG
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):101-8. PubMed ID: 22658512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.
    van den Bergh RC; van Casteren NJ; van den Broeck T; Fordyce ER; Gietzmann WK; Stewart F; MacLennan S; Dabestani S; Bellmunt J; Bolla M; Briers E; Cornford P; Joniau S; Mason MD; Matveev V; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Lam TB; Mottet N
    Eur Urol; 2016 May; 69(5):802-20. PubMed ID: 26691493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of PSA only recurrence of prostate cancer after prior local therapy.
    Moul JW
    Curr Pharm Des; 2006; 12(7):785-98. PubMed ID: 16515495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
    Schröder FH; Bangma CH; Wolff JM; Alcaraz A; Montorsi F; Mongiat-Artus P; Abrahamsson PA; McNicholas TA; Castro RS; Nandy IM
    BJU Int; 2009 Mar; 103(5):590-6. PubMed ID: 19226424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy.
    Moul JW
    Mol Urol; 2000; 4(3):267-71;discussion 273. PubMed ID: 11062383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
    Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
    Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N; Klotz L; Crook J; Goldenberg SL
    Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
    Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
    Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment for biochemical relapse after radiotherapy.
    Quero L; Hennequin C
    Cancer Radiother; 2014 Oct; 18(5-6):540-4. PubMed ID: 25179255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormonal treatment in biochemical recurrence after radical prostatectomy].
    Antolín AR; Ojeda JM; Otero JR; Rodríguez AC; Castellano D; Esteban MD; Sicilia LD; González RD
    Arch Esp Urol; 2012; 65(1):111-21. PubMed ID: 22318183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.